Magazine Article | February 1, 2019

Master Trial Protocols: Better For Pharma, Better For Sites

Source: Life Science Leader

By Ed Miseta, Chief Editor, Clinical Leader
Follow Me On Twitter @EdClinical

Over the last few years there have been increased discussions in the industry around a master protocol approach to clinical trials. Lori Carman, VP of clinical operations at CytomX Therapeutics, believes those discussions have really accelerated in the past year. This has been spurred on by the FDA, which in September 2018 released draft guidelines on this topic for the industry.